Full Title
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Hamza Hashmi’s office at 646-608-4348.
Protocol
26-218
Phase
Phase III (phase 3)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07391657
ClinicalTrials.gov